[go: up one dir, main page]

AU2001263329A1 - Crf receptor antagonists and methods relating thereto - Google Patents

Crf receptor antagonists and methods relating thereto

Info

Publication number
AU2001263329A1
AU2001263329A1 AU2001263329A AU6332901A AU2001263329A1 AU 2001263329 A1 AU2001263329 A1 AU 2001263329A1 AU 2001263329 A AU2001263329 A AU 2001263329A AU 6332901 A AU6332901 A AU 6332901A AU 2001263329 A1 AU2001263329 A1 AU 2001263329A1
Authority
AU
Australia
Prior art keywords
crf receptor
receptor antagonists
methods relating
crf
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001263329A
Inventor
Mustapha Haddach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
Original Assignee
Neurocrine Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc filed Critical Neurocrine Biosciences Inc
Publication of AU2001263329A1 publication Critical patent/AU2001263329A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animal, such as stroke. The CRF receptor antagonists of this invention have the following structure: including stereoisomers and pharmaceutically acceptable salts thereof, wherein m, R, R1, R2, A, and X are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.
AU2001263329A 2000-05-18 2001-05-18 Crf receptor antagonists and methods relating thereto Abandoned AU2001263329A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20564900P 2000-05-18 2000-05-18
US60205649 2000-05-18
PCT/US2001/016326 WO2001087889A1 (en) 2000-05-18 2001-05-18 Crf receptor antagonists and methods relating thereto

Publications (1)

Publication Number Publication Date
AU2001263329A1 true AU2001263329A1 (en) 2001-11-26

Family

ID=22763066

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001263329A Abandoned AU2001263329A1 (en) 2000-05-18 2001-05-18 Crf receptor antagonists and methods relating thereto

Country Status (8)

Country Link
US (2) US6541469B2 (en)
EP (1) EP1282624B1 (en)
JP (1) JP2003533527A (en)
AT (1) ATE260918T1 (en)
AU (1) AU2001263329A1 (en)
DE (1) DE60102231T2 (en)
ES (1) ES2214422T3 (en)
WO (1) WO2001087889A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE260918T1 (en) * 2000-05-18 2004-03-15 Neurocrine Biosciences Inc CRF RECEPTOR ANTAGONISTS AND RELATED METHODS
CA2478715A1 (en) 2002-03-13 2003-09-25 Pharmacia & Upjohn Company Novel pyrazolo [1,5-a]pyridine derivatives and their use as neurotransmitter modulators
US20060024661A1 (en) * 2003-07-30 2006-02-02 The Regents Of The University Of California Modulation of CRF potentiation of NMDA receptor currents via CRF receptor 2
ATE356129T1 (en) * 2004-01-06 2007-03-15 Taisho Pharmaceutical Co Ltd TRIAZACYCLOPENTA(CD)INDENDERIVATES
US7869958B2 (en) * 2004-08-09 2011-01-11 Research Development Foundation Structure-based modulators of B1 G-protein coupled receptors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6191131B1 (en) * 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
SI1049699T1 (en) 1998-01-28 2004-10-31 Bristol-Myers Squibb Pharma Company Pyrazolotriazines as crf antagonists
CN1178941C (en) * 1998-11-12 2004-12-08 纽罗克里恩生物科学有限公司 CRF receptor antagonists and methods related thereto
ATE260918T1 (en) * 2000-05-18 2004-03-15 Neurocrine Biosciences Inc CRF RECEPTOR ANTAGONISTS AND RELATED METHODS

Also Published As

Publication number Publication date
EP1282624B1 (en) 2004-03-03
EP1282624A1 (en) 2003-02-12
DE60102231D1 (en) 2004-04-08
WO2001087889A1 (en) 2001-11-22
JP2003533527A (en) 2003-11-11
ATE260918T1 (en) 2004-03-15
US20020032194A1 (en) 2002-03-14
ES2214422T3 (en) 2004-09-16
US20040014747A1 (en) 2004-01-22
US6541469B2 (en) 2003-04-01
DE60102231T2 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
WO2000027846A3 (en) Crf receptor antagonists and methods relating thereto
IL155702A0 (en) Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5-ht2 receptor
DK1646389T3 (en) Pyrimidine-2,4-dione derivatives as gonadotropin-releasing hormone receptor antagonists
WO2001066534A3 (en) Cyclic and bicyclic diamino histamine-3 receptor antagonists
WO2006044821A8 (en) Crf receptor antagonists and methods relating thereto
TR200102178T2 (en) CRF receptor antagonists and related methods.
AU2003228674A1 (en) Muscarinic antagonists
IL172834A0 (en) Pyrimidine-,2,4-dione derivatives and pharmaceutical compositions containing the same
WO2004112704A3 (en) Substituted piperidine compounds and methods of their use
IL158806A0 (en) Tri-and tetraaza-acenaphthylen derivatives as crf receptor antagonists
MXPA03003714A (en) Crf receptor antagonists and methods relating thereto.
AU2001261850A1 (en) Crf receptor antagonists and methods relating thereto
AU2001263329A1 (en) Crf receptor antagonists and methods relating thereto
EP1786815A4 (en) Spiro compounds and methods for the modulation of chemokine receptor activity
IL161600A0 (en) Compounds and method for the treatment of over-active bladder
DE602004012318D1 (en) CRF RECEPTOR ANTAGONISTS AND METHODS OF THIS INVENTION